Search
Rolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalBy blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and
Certolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigational[A176606] Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be … [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819]
Valganciclovir
go.drugbank.com/drugs/DB01610ApprovedInvestigationalValganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. … After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
Icosapent
go.drugbank.com/drugs/DB00159ApprovedInvestigationalNutraceuticalImportant polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovas...
Mixtures: Se-Tan DHA, Se-Tan DHAMelphalan
go.drugbank.com/drugs/DB01042ApprovedInvestigational[L40928] It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.
Stem bromelain
go.drugbank.com/drugs/DB12249ApprovedThis action allows bromelain to demonstrate a wide range of therapeutic benefits ranging from cardiovascular to anticancer therapy - but the specific mechanisms of action by which it can elicit these effects … Bromelain is consequently a composite mixture of several different endopeptidases that can facilitate many different reactions with many different substrates.
Vamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigationalVamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals. … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.
Hexylresorcinol
go.drugbank.com/drugs/DB11254ApprovedIt can be found in topical applications for minor skin infections and in oral solutions or throat lozenges for pain relief and first aid antiseptic. … The compound may also be used commonly in various commercial cosmetic anti-aging creams while ongoing studies research the possibility of using hexylresorcinol as an anti-cancer therapy - indications all
Glucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[A244750] Glucarpidase is an enzyme that can rapidly hydrolyze methotrexate into its nontoxic metabolites. … This can lead to delayed renal clearance of methotrexate and elevated drug plasma levels, increasing the risk of methotrexate toxicity.
Sebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalHereditary angioedema (HAE) is a rare genetic disease that causes sudden, painful swelling episodes in various body locations that can be life-threatening, particularly when affecting the throat [L53533 … This plasma kallikrein inhibitor works by reducing bradykinin, the substance that causes the characteristic swelling in HAE attacks [L53533]. The U.S.